CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
paricalcitol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00990704
NCT00990704Phase 2Completed
CompareCT.gov

Phase II, Open Study, Exploratory Examination of Efficacy and Safety of Paricalcitol Injection and Maxacalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism

Abbott·interventional·Posted Oct 7, 2009·Updated Jul 11, 2011

In Brief

A Phase 2 clinical trial evaluating paricalcitol and maxacalcitol for Secondary Hyperparathyroidism and Hemodialysis. Completed, enrolled 47 participants across 14 sites.

Detailed Summary

This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSecondary Hyperparathyroidism, Hemodialysis
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 7, 2009
Enrollment StartOct 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.7 years ago

Interventions

paricalcitoldrug

Intravenous administration 3 times a week immediately before completion of dialysis

maxacalcitoldrug

Intravenous administration 3 times a week immediately before completion of dialysis